Hikma and Arecor today announce they have entered into a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc. The agreement builds on Hikma and Arecor’s first product co-development agreement, which was announced on 9 January 2020.
Arcinova, a multi-service Contract Development and Manufacturing Organisation (CDMO) based in Alnwick, Northumberland, has recently taken delivery and commissioned the award winning R1000 Robotic Capsule Filler from life-sciences automation company 3P innovation, as part of the ‘Fill-Inova’ project.
It’s our Annual General Meeting this week which you can join on Zoom and I’m expecting a big week for Brexit.
Thank you to members who stood for and voted in our Board election in recent weeks. The results will be announced at our first virtual AGM this Wednesday and I invite all members to join. For the full meeting details and password, please email Nick Gardiner email@example.com He will also be circulating these details to all main members shortly.
European law firm Fieldfisher has advised AIM-quoted Synairgen plc, a leading respiratory disease drug discovery company based in Southampton, on its £87 million fundraising to begin the Phase III trial for a potential inhaled treatment for COVID-19
• Iksuda licenses novel protein-alkylating, tumour-activated pro-drug payload series to develop ADCs with
enhanced therapeutic index
• Development to focus on targets associated with haematological and solid tumours
The BIA’s latest investment report shows a record quarter for investment in the UK biotech sector, Nobel prizes and Honours for the sector, plus Tony Blair joins us for a keynote session at our flagship autumn conference, the UK Bioscience Forum.
New data published today by the BioIndustry Association (BIA) and Clarivate reveals that UK biotech companies raised more than £1billion in equity finance between June and August 2020, the highest quarter for investments in the sector on record.
The UK genomic tools developer, RevoluGen Ltd. (‘RevoluGen or the Company), today announces it has entered into a non-exclusive distribution agreement with Welgene Biotech Co., Ltd. (‘Welgene’) of Taiwan, for the distribution of its Fire Monkey/Fire Flower High Molecular Weight DNA (HMW-DNA) extraction and purification product.
The BIA’s UK Bioscience Forum takes place next week 14-15 October and will focus on the opportunities and challenges of Emerging Data Technologies in the life sciences. The full programme is available here featuring speakers from IQVIA, NICE, Benevolent AI, Lifebit, Babylon, AWS, Deepmatter, Closed Loop Medicine, Mogrify, Elsevier, Stratagem IPM, Microsoft, Illumina, Novartis Biome, Milner Therapeutics Institute, Oxford Nanopore, UK Biobank, IBM, Sensyne and UKRI amongst others.